Publications by authors named "Ryo Ariyasu"

Claim this Profile
T
The first case of fusion-positive malignant spindle cell sarcoma of the head and neck responsive to selpercatinib.
Takehiro Nakao, Naoki Fukuda, Xiaofei Wang, Ryosuke Oki, Tetsuya Urasaki, Ryo Ariyasu

Int Cancer Conf J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor.
Hirokazu Iso, Ryo Ariyasu, Syunsuke Fujishima, Masahiro Ito, Kyujiro Nibuya

Lung Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure.
Yoh Yamaguchi, Yuki Shinno, Ken Masuda, Ryo Ariyasu, Kaname Nosaki

Curr Probl Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens.
Mayu Sugai, Yoshiaki Amino, Shunsuke Fujishima, Kyujiro Nibuya, Hirokazu Iso, Ryo Ariyasu

Lung Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-Stratified Risk of Carboplatin-Induced Nausea and Vomiting in Lung Cancer Patients.
Koki Hashimoto, Takashi Yokokawa, Yuma Nonomiya, Naoki Shibata, Azusa Soejima, Ryo Ariyasu

Oncology· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Keiki Miyadera, Sho Kakuto, Mayu Sugai, Ryosuke Tsugitomi, Yoshiaki Amino, Ryo Ariyasu

Cancers (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling.
Yuto Naoi, Takao Morinaga, Joji Nagasaki, Ryo Ariyasu, Youki Ueda

Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani

Thorac Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Ryo Ariyasu

Thorac Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.
Shinsuke Ogusu, Yuhei Harutani, Takehiro Tozuka, Ryota Saito, Junji Koyama, Ryo Ariyasu

Cancer Immunol Immunother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics of patients with KRAS mutation detected by liquid biopsy.
Yoshiaki Amino, Siew-Kee Low, Hironori Ninomiya, Ayu Kiritani, Keiki Miyadera, Ryo Ariyasu

Thorac Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).
Tsukasa Hasegawa, Ryo Ariyasu, Hisashi Tanaka, Ryota Saito, Yosuke Kawashima

Cancer Chemother Pharmacol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients.
Takehiro Tozuka, Noriko Yanagitani, Hiroshi Yoshida, Ryo Manabe, Shinsuke Ogusu, Ryo Ariyasu

Invest New Drugs· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors.
Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Takahiro Akita, Ayu Kiritani

JTO Clin Res Rep· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients.
Kohei Hashimoto, Ryo Ariyasu, Junji Ichinose, Yosuke Matsuura, Masayuki Nakao

J Thorac Cardiovasc Surg· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myocarditis associated with immune-checkpoint inhibitors diagnosed by cardiac magnetic resonance imaging.
Masafumi Fukumitsu, Ryo Ariyasu, Mitsutomi Ishiyama, Toshiaki Mochizuki, Koichi Takeda

Int Cancer Conf J· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy.
Shinsuke Ogusu, Ryo Ariyasu, Takahiro Akita, Ayu Kiritani, Ryosuke Tsugitomi

Invest New Drugs· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus™ integrated sequencer.
Siew-Kee Low, Ryo Ariyasu, Ken Uchibori, Rie Hayashi, Hiu Ting Chan

Transl Lung Cancer Res· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes.
Joji Nagasaki, Takashi Inozume, Nicolas Sax, Ryo Ariyasu, Masakazu Ishikawa

Cell Rep· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of central nervous system progression in non-small cell lung cancer treated with crizotinib or alectinib.
Hiroaki Sakamoto, Noriko Yanagitani, Ryo Manabe, Ryosuke Tsugitomi, Shinsuke Ogusu, Ryo Ariyasu

Cancer Rep (Hoboken)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
Ryo Ariyasu, Ken Uchibori, Takaaki Sasaki, Mika Tsukahara, Kazuma Kiyotani

Cancer Sci· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients.
Takehiro Tozuka, Noriko Yanagitani, Hiroshi Yoshida, Ryo Manabe, Shinsuke Ogusu, Ryo Ariyasu

Anticancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.
Takahiro Yoshizawa, Ken Uchibori, Mitsugu Araki, Shigeyuki Matsumoto, Biao Ma, Ryo Ariyasu

NPJ Precis Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical influence of switching companion diagnostic tests for EGFR-TKs from Therascreen to Cobas v2.
Ken Uchibori, Natsuki Takano, Ryo Manabe, Ryosuke Tsugitomi, Shinsuke Ogusu, Ryo Ariyasu

Thorac Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice.
Ryo Ariyasu, Ken Uchibori, Hironori Ninomiya, Shinsuke Ogusu, Ryosuke Tsugitomi

Thorac Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis